- Home
- ZD vs KOD Comparison
ZD vs KOD Comparison
Compare ZD & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZD | KOD |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZD | KOD |
|---|---|---|
| Price | $27.16 | $26.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $36.50 | $28.29 |
| AVG Volume (30 Days) | ★ 693.3K | 613.9K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,364,028,000.00 | N/A |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $3.36 | N/A |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.45 | $1.92 |
| 52 Week High | $43.54 | $31.18 |
Technical Indicators
Market Signals| Indicator | ZD | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 31.59 | 54.39 |
| Support Level | N/A | $23.92 |
| Resistance Level | $33.47 | $30.34 |
| Average True Range (ATR) | 2.00 | 1.92 |
| MACD | -0.45 | 0.53 |
| Stochastic Oscillator | 40.23 | 70.45 |
Price Performance
Historical ComparisonAbout ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.